Medtronic Balances Courtroom Pressure With Regulatory Momentum as MiniMed Exchange Deadline Looms
Published on 10/09/2026 at 16:02 | Editorial boerse-global.de
Medtronic finds itself navigating two very different fronts this week: a fresh antitrust challenge in its home market and a steady drumbeat of regulatory and reimbursement wins across its device portfolio. The tension between legal risk and pipeline execution is shaping how investors view the medtech giant right now.
Applied Medical Seeks Permanent Injunction
Applied Medical Resources filed a response in court on October 2 demanding a permanent injunction against Medtronic, according to media reports. The competitor's filing centers on allegations that Medtronic has monopolized the market for advanced bipolar energy instruments — the tools surgeons rely on in operating rooms. Applied Medical is pushing for a lasting ban on certain sales practices, claiming the company abused its market position to entrench itself.
Antitrust battles of this kind carry strategic weight for established device makers, since they can threaten distribution arrangements that underpin revenue in core surgical categories. Medtronic has not signaled how it intends to respond.
FDA Breakthrough Tag for IN.PACT BTK
On the regulatory side, the FDA granted Breakthrough Device designation to Medtronic's IN.PACT BTK drug-coated balloon. The company disclosed the decision on September 30, noting the product will be studied in a randomized pivotal trial. The designation is reserved for therapies targeting life-threatening or irreversibly debilitating conditions, and it opens a faster review pathway.
Should investors sell immediately? Or is it worth buying Medtronic?
That same day, Medtronic reported CE marking for its PulseSelect ProxBox adapter, which runs Proximity-Indicator software. Three days later, on October 3, came fresh data from the Spectrum program covering the VenaSeal closure system in advanced chronic venous disease. Reimbursement for the procedure now reaches 96 percent of people in the U.S. covered by Medicare or commercial insurance — a critical threshold, since device makers depend on payer coverage to move novel procedures beyond isolated cases into routine clinical use. Medtronic's approach ties clinical evidence generation directly to reimbursement filings.
Billing Codes Lock In Long-Term Framework
Reimbursement infrastructure got a boost on October 1, when the American Medical Association approved new Category-I CPT codes for the Altaviva and Symplicity Spyral systems. Altaviva handles tibial neuromodulation, while Symplicity Spyral is used for renal denervation. The codes take effect in January 2028 and give physicians a durable billing pathway for both therapies under the U.S. system.
Clinical momentum continued through the week. Medtronic presented TITAN-2 results for treating nocturia, and named Ariana L. Smith of Penn Medicine as lead investigator for the follow-up ENDURANCE trial. On Wednesday, the company secured clearance for navigated ApexCut EM blades for sinus surgery, with first U.S. procedures slated for 2026. The pattern across these launches is consistent: new surgical tools paired with in-house navigation software.
MiniMed Exchange Ratio Set at 4.5939
Running alongside the clinical work is a corporate restructuring. Medtronic fixed the final exchange ratio for the MiniMed Group separation at 4.5939 MiniMed shares per Medtronic share tendered — a swap covering up to 225,361,295 MiniMed shares. The offer runs until midnight New York time on October 9, 2026, unless extended.
The company's fiscal 2026 report showed research and development spending of $2.9 billion, alongside disclosure that its devices have reached more than 82 million patients worldwide.
Barclays Stays on the Sidelines
Barclays rated Medtronic Equal Weight, with a price target of $95. The stock slipped 0.2 percent to EUR 78.06 in today's session, putting the company's market value at roughly EUR 97.59 billion. Whether management can resolve the Applied Medical dispute quickly — and keep its new therapies rolling out unimpeded — remains the question driving sentiment.
Ad
Medtronic Stock: New Analysis - 9 October
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
